Ernexa Therapeutics (NASDAQ:ERNA) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Ernexa Therapeutics (NASDAQ:ERNA) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other analysts have also issued reports on ERNA. Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They set a “buy” rating and a $30.00 price target on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Friday, July 17th. Finally, Zacks Research raised shares of Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Trading Up 7.6%

ERNA stock opened at $4.53 on Friday. The company has a market capitalization of $5.30 million, a PE ratio of -0.32 and a beta of 2.57. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $71.50. The business’s fifty day moving average price is $5.78 and its 200 day moving average price is $8.52.

Ernexa Therapeutics (NASDAQ:ERNA) last posted its earnings results on Thursday, August 6th. The company reported ($3.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.30) by ($0.10). Research analysts predict that Ernexa Therapeutics will post -18.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 70.55% of the company’s stock.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.